A comparative evaluation of β-catenin and plakoglobin signaling activity

被引:53
作者
Williams, BO
Barish, GD
Klymkowsky, MW
Varmus, HE
机构
[1] NCI, Div Basic Sci, NIH, Bethesda, MD 20892 USA
[2] Univ Colorado, Boulder, CO 80309 USA
关键词
beta-catenin; plakoglobin; Wnt; LEF/TCF;
D O I
10.1038/sj.onc.1203921
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Vertebrates have two Armadillo-like proteins, beta -catenin and plakoglobin. Mutant forms of beta -catenin with oncogenic activity are found in many human tumors, but plakoglobin mutations are not commonly found, In fact, plakoglobin has been proposed to suppress tumorigenesis, To assess differences between beta -catenin and plakoglobin, we compared several of their biochemical properties, After transient transfection of 293T cells with an expression vector encoding either of the two proteins, soluble wild type beta -catenin does not significantly accumulate, whereas soluble wild type plakoglobin is readily detected. As anticipated, beta -catenin is stabilized by the oncogenic mutation S37A; however, the analogous mutation in plakoglobin (S28A) does not alter its half-life. S37A-beta -catenin activates a TCF/LEF-dependent reporter 20-fold more potently than wild type beta -catenin, and similar to5-fold more potently than wild type or S28A plakoglobin. These differences may be attributable to an enhanced affinity of S37A beta -catenin for LEF1 and TCF4, as observed here by immunoprecipitation assays. We show that the carboxyl-terminal domain is largely responsible for the difference in signaling and that the Armadillo repeats account for the remainder of the difference, The relatively weak signaling by plakoglobin and the failure of the S28A mutation to enhance its stability, may explain why plakoglobin mutations are infrequent in malignancies.
引用
收藏
页码:5720 / 5728
页数:9
相关论文
共 89 条
[1]  
Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.3.CO
[2]  
2-D
[3]   THE HUMAN PLAKOGLOBIN GENE LOCALIZES ON CHROMOSOME 17Q21 AND IS SUBJECTED TO LOSS OF HETEROZYGOSITY IN BREAST AND OVARIAN CANCERS [J].
ABERLE, H ;
BIERKAMP, C ;
TORCHARD, D ;
SEROVA, O ;
WAGNER, T ;
NATT, E ;
WIRSCHING, J ;
HEIDKAMPER, C ;
MONTAGNA, M ;
LYNCH, HT ;
LENOIR, GM ;
SCHERER, G ;
FEUNTEUN, J ;
KEMLER, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (14) :6384-6388
[4]  
Barker N, 2000, ADV CANCER RES, V77, P1
[5]   Cadherins, catenins and APC protein: interplay between cytoskeletal complexes and signaling pathways [J].
Barth, AI ;
Nathke, IS ;
Nelson, WJ .
CURRENT OPINION IN CELL BIOLOGY, 1997, 9 (05) :683-690
[6]   Functional interaction of an axin homolog, conductin, with β-catenin, APC, and GSK3β [J].
Behrens, J ;
Jerchow, BA ;
Würtele, M ;
Grimm, J ;
Asbrand, C ;
Wirtz, R ;
Kühl, M ;
Wedlich, D ;
Birchmeier, W .
SCIENCE, 1998, 280 (5363) :596-599
[7]   Functional interaction of beta-catenin with the transcription factor LEF-1 [J].
Behrens, J ;
vonKries, JP ;
Kuhl, M ;
Bruhn, L ;
Wedlich, D ;
Grosschedl, R ;
Birchmeier, W .
NATURE, 1996, 382 (6592) :638-642
[8]  
Bierkamp C, 1999, DEVELOPMENT, V126, P371
[9]   A beta-catenin/XTcf-3 complex binds to the siamois promoter to regulate dorsal axis specification in Xenopus [J].
Brannon, M ;
Gomperts, M ;
Sumoy, L ;
Moon, RT ;
Kimelman, D .
GENES & DEVELOPMENT, 1997, 11 (18) :2359-2370
[10]  
Caca K, 1999, CELL GROWTH DIFFER, V10, P369